BioNTech Beats Expectations, Gives Update on Cancer Drugs

Bloomberg11-04

BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

陈沛嫣
11-04
陈沛嫣
Share your opinion about this news…

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1189866244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-04 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189866244","market":"us","top_or_hot":-1,"title":"BioNTech Beats Expectations, Gives Update on Cancer Drugs","media":"Bloomberg","content":"<div>\n<p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs\">Source Link</a>\n\n</div>\n","source":"lsy1584095487587","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Beats Expectations, Gives Update on Cancer Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Beats Expectations, Gives Update on Cancer Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNTX","symbol_name":"BioNTech SE","start_time":0,"source_url":"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs","article_id":"1189866244","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189866244","pubTimestamp":1730726556,"columns":[],"sourceInfo":{"source_id":"lsy1584095487587","name":"Bloomberg"},"weMediaInfo":null,"summary":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s e","collect":0,"end_time":0,"defaultTopTitle":"bloomberg.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BNTX":"BioNTech SE"},"translate_title":"BioNTech超出预期，提供癌症药物最新信息","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1.1},"content_text":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.Sales came in almost three times higher than anticipated at €1.2 billion, although the company said it still expects to be at the low end of its full-year revenue range of between €2.5 billion to €3.1 billion.The beat in revenue was largely a result of BioNTech receiving early regulatory approvals in Europe and the UK for its variant-adapted Covid-19 shots, which it makes with Pfizer Inc. That boosted sales compared with the same time last year.BioNTech gained prominence during the pandemic and still remains dependent on Covid-19 jabs. But it said it’s advancing efforts to become a global multiproduct immunotherapy company, with various cancer drugs and vaccine candidates in its pipeline.The company has initiated two mid-stage dose optimization studies including for its widely-watched experimental medicine in small-cell lung cancer and triple-negative breast cancer. A mid-stage trial of an mRNA-based individualized cancer vaccine for use in patients with high-risk muscle-invasive urothelial cancer is also on track, it said.The vaccine maker has suffered a setback for its two-in-one shot against Covid and the flu that it’s developing with Pfizer.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":367461493068120,"gmtCreate":1730727384489,"gmtModify":1730727437731,"author":{"id":"3576038173431541","authorId":"3576038173431541","name":"陈沛嫣","avatar":"https://static.tigerbbs.com/f516132514df0424f07a465da205ada0","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3576038173431541","authorIdStr":"3576038173431541"},"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/367461493068120","repostId":1189866244,"repostType":2,"repost":{"id":"1189866244","kind":"news","pubTimestamp":1730726556,"share":"https://ttm.financial/m/news/1189866244?lang=&edition=fundamental","pubTime":"2024-11-04 21:22","market":"us","language":"en","title":"BioNTech Beats Expectations, Gives Update on Cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=1189866244","media":"Bloomberg","summary":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s e","content":"<html><head></head><body><p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.</p><p>BioNTech shares gained 3% in premarket trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/89277731b77ac2bcad91d40d2742919b\" tg-width=\"828\" tg-height=\"840\"/></p><p style=\"text-align: start;\">Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.</p><p style=\"text-align: start;\">Sales came in almost three times higher than anticipated at €1.2 billion, although the company said it still expects to be at the low end of its full-year revenue range of between €2.5 billion to €3.1 billion.</p><p style=\"text-align: start;\">The beat in revenue was largely a result of BioNTech receiving early regulatory approvals in Europe and the UK for its variant-adapted Covid-19 shots, which it makes with Pfizer Inc. That boosted sales compared with the same time last year.</p><p style=\"text-align: start;\">BioNTech gained prominence during the pandemic and still remains dependent on Covid-19 jabs. But it said it’s advancing efforts to become a global multiproduct immunotherapy company, with various cancer drugs and vaccine candidates in its pipeline.</p><p style=\"text-align: start;\">The company has initiated two mid-stage dose optimization studies including for its widely-watched experimental medicine in small-cell lung cancer and triple-negative breast cancer. A mid-stage trial of an mRNA-based individualized cancer vaccine for use in<em> </em>patients with high-risk muscle-invasive urothelial cancer is also on track, it said.</p><p style=\"text-align: start;\">The vaccine maker has suffered a setback for its two-in-one shot against Covid and the flu that it’s developing with Pfizer.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech Beats Expectations, Gives Update on Cancer Drugs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech Beats Expectations, Gives Update on Cancer Drugs\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-04 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BNTX":"BioNTech SE"},"source_url":"https://www.bloomberg.com/news/articles/2024-11-04/biontech-beats-expectations-gives-update-on-cancer-drugs","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1189866244","content_text":"BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.BioNTech shares gained 3% in premarket trading.Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ($0.88) in the third quarter, according to a statement Monday. Analysts surveyed by Bloomberg expected a loss of €1.84.Sales came in almost three times higher than anticipated at €1.2 billion, although the company said it still expects to be at the low end of its full-year revenue range of between €2.5 billion to €3.1 billion.The beat in revenue was largely a result of BioNTech receiving early regulatory approvals in Europe and the UK for its variant-adapted Covid-19 shots, which it makes with Pfizer Inc. That boosted sales compared with the same time last year.BioNTech gained prominence during the pandemic and still remains dependent on Covid-19 jabs. But it said it’s advancing efforts to become a global multiproduct immunotherapy company, with various cancer drugs and vaccine candidates in its pipeline.The company has initiated two mid-stage dose optimization studies including for its widely-watched experimental medicine in small-cell lung cancer and triple-negative breast cancer. A mid-stage trial of an mRNA-based individualized cancer vaccine for use in patients with high-risk muscle-invasive urothelial cancer is also on track, it said.The vaccine maker has suffered a setback for its two-in-one shot against Covid and the flu that it’s developing with Pfizer.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":5,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1189866244"}